Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2020 · 10-Q
Revenue$86.98M$86.98M−14.5% vs Q2 2019 Net Income-$6.82M-$6.82MN/M vs Q2 2019 EPS Diluted-$0.06-$0.06N/M vs Q2 2019 Gross Profit$28,006,000−42.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,882,000N/M Free Cash Flowderived-$3,144,000N/M Margins · derivedGross margin32.2%−15.9 pt vs Q2 2019
Operating margin-21.7%−26.1 pt vs Q2 2019
Net margin-7.8%−9.8 pt vs Q2 2019
ended Jun 30, 2020 · filed Jul 31, 2020 · 31 d after period end